First hypertension device therapy reaches Europe:
This article was originally published in Clinica
The first ever device therapy for hypertension has been CE marked for sale in Europe. CVRx's Rheos baroreflex hypertension therapy system is an implantable device that electronically activates the patient's baroreflex - the body's own system for controlling blood pressure. The company is now enrolling patients in a US pivotal trial for the technology. Outcomes from the study will be used to support a premarket approval application to the US FDA. The Minneapolis, Minnesota company claims that hypertension affects some 65 million in the US alone. Of these, around 25% cannot control their high blood pressure despite the use of multiple therapies.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.